Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois (M.K., D.D.L., J.O., J.E.B.); and Department of Chemistry and Biochemistry, University of North Carolina Wilmington, Wilmington, North Carolina (L.J.D.).
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois (M.K., D.D.L., J.O., J.E.B.); and Department of Chemistry and Biochemistry, University of North Carolina Wilmington, Wilmington, North Carolina (L.J.D.)
Mol Pharmacol. 2024 Aug 16;106(3):145-154. doi: 10.1124/molpharm.124.000921.
Ovarian cancer, the fifth leading cause of cancer-related mortality in women, is the most lethal gynecological malignancy globally. Within various ovarian cancer subtypes, high-grade serous ovarian cancer is the most prevalent and there is frequent emergence of chemoresistance. Aulosirazole, an isothiazolonaphthoquinone alkaloid, isolated from the cyanobacterium sp. UIC 10771, demonstrated cytotoxic activity against OVCAR3 cells (IC = 301 ± 80 nM). Using immunocytochemistry, OVCAR3 cells treated with aulosirazole demonstrated increased concentrations of phosphorylated protein kinase B and phosphorylated c-Jun N-terminal kinase with subsequent accumulation of forkhead box O3a (FOXO3a) in the nucleus. The combination of aulosirazole with protein kinase B inhibitors resulted in the most nuclear accumulation of FOXO3a aulosirazole-induced apoptosis based on cleavage of poly(ADP-ribose) polymerase, annexin V staining, and induction of caspase 3/7 activity in OVCAR3, OVCAR5, and OVCAR8. The expression of downstream targets of FOXO3a, including B-cell lymphoma 2 (BCL2) and p53-upregulator modulator of apoptosis, increased following aulosirazole treatment. Aulosirazole upregulated the FOXO3a target, cyclin-dependent kinase inhibitor 1, and increased cell-cycle arrest in the G0/G1 phase. The downregulation of FOXO3a by short hairpin RNA (shRNA) reduced the cytotoxicity after aulosirazole treatment by 3-fold IC (949 ± 16 nM) and eliminated its ability to regulate downstream targets of FOXO3a. These findings underscore FOXO3a as a critical mediator of aulosirazole-induced cytotoxicity. Additionally, aulosirazole was able to decrease migration and invasion while increasing cell death in 3D tumor spheroids. However, in vivo OVCAR8 tumor burden was not reduced by aulosirazole using an intraperitoneal tumor model. Given the mechanism of action of aulosirazole, this class of alkaloids represents promising lead compounds to develop treatments against FOXO3a-downregulated cancers. SIGNIFICANCE STATEMENT: Aulosirazole, an isothiazolonaphthoquinone alkaloid, exhibits potent cytotoxic effects against high-grade serous ovarian cancer by promoting forkhead box O3a (FOXO3a) nuclear accumulation and modulating downstream targets. These findings highlight the potential of aulosirazole as a promising therapeutic intervention for cancers characterized by FOXO3a downregulation.
卵巢癌是女性癌症相关死亡的第五大主要原因,是全球最致命的妇科恶性肿瘤。在各种卵巢癌亚型中,高级别浆液性卵巢癌最为常见,并且经常出现化疗耐药性。从蓝藻 sp. UIC 10771 中分离出的异噻唑并萘醌生物碱 aulosirazole 对 OVCAR3 细胞表现出细胞毒性作用(IC = 301 ± 80 nM)。通过免疫细胞化学,用 aulosirazole 处理的 OVCAR3 细胞显示出磷酸化蛋白激酶 B 和磷酸化 c-Jun N-末端激酶浓度增加,随后叉头框 O3a(FOXO3a)在核内积累。aulosirazole 与蛋白激酶 B 抑制剂的联合使用导致基于多聚(ADP-核糖)聚合酶的切割、膜联蛋白 V 染色和 caspase 3/7 活性诱导的 aulosirazole 诱导的凋亡中 FOXO3a 的核内积累最多,在 OVCAR3、OVCAR5 和 OVCAR8 中。FOXO3a 的下游靶标,包括 B 细胞淋巴瘤 2(BCL2)和凋亡上调因子 p53 调节剂,在 aulosirazole 处理后表达增加。aulosirazole 上调了 FOXO3a 靶标细胞周期蛋白依赖性激酶抑制剂 1,并增加了细胞周期在 G0/G1 期的停滞。短发夹 RNA(shRNA)下调 FOXO3a 可使 aulosirazole 处理后的细胞毒性降低 3 倍 IC(949 ± 16 nM),并消除其调节 FOXO3a 下游靶标的能力。这些发现强调了 FOXO3a 作为 aulosirazole 诱导的细胞毒性的关键介质。此外,aulosirazole 能够减少 3D 肿瘤球体中的迁移和侵袭,同时增加细胞死亡。然而,在使用腹腔内肿瘤模型时,aulosirazole 并未降低 OVCAR8 肿瘤负担。鉴于 aulosirazole 的作用机制,这类生物碱代表了开发针对 FOXO3a 下调癌症治疗方法的有前途的先导化合物。
异噻唑并萘醌生物碱 aulosirazole 通过促进叉头框 O3a(FOXO3a)核内积累和调节下游靶标,对高级别浆液性卵巢癌表现出强烈的细胞毒性作用。这些发现突出了 aulosirazole 作为一种有前途的治疗干预手段的潜力,用于治疗特征为 FOXO3a 下调的癌症。